379 related articles for article (PubMed ID: 34404389)
1. Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.
Haverfield EV; Esplin ED; Aguilar SJ; Hatchell KE; Ormond KE; Hanson-Kahn A; Atwal PS; Macklin-Mantia S; Hines S; Sak CW; Tucker S; Bleyl SB; Hulick PJ; Gordon OK; Velsher L; Gu JYJ; Weissman SM; Kruisselbrink T; Abel C; Kettles M; Slavotinek A; Mendelsohn BA; Green RC; Aradhya S; Nussbaum RL
BMC Med; 2021 Aug; 19(1):199. PubMed ID: 34404389
[TBL] [Abstract][Full Text] [Related]
2. At-Risk Genomic Findings for Pediatric-Onset Disorders From Genome Sequencing vs Medically Actionable Gene Panel in Proactive Screening of Newborns and Children.
Balciuniene J; Liu R; Bean L; Guo F; Nallamilli BRR; Guruju N; Chen-Deutsch X; Yousaf R; Fura K; Chin E; Mathur A; Ma Z; Carmichael J; da Silva C; Collins C; Hegde M
JAMA Netw Open; 2023 Jul; 6(7):e2326445. PubMed ID: 37523181
[TBL] [Abstract][Full Text] [Related]
3. Actionable secondary findings following exome sequencing of 836 non-obstructive azoospermia cases and their value in patient management.
Kasak L; Lillepea K; Nagirnaja L; Aston KI; Schlegel PN; Gonçalves J; Carvalho F; Moreno-Mendoza D; Almstrup K; Eisenberg ML; Jarvi KA; O'Bryan MK; Lopes AM; Conrad DF; ; Punab M; Laan M
Hum Reprod; 2022 Jun; 37(7):1652-1663. PubMed ID: 35535697
[TBL] [Abstract][Full Text] [Related]
4. High-frequency actionable pathogenic exome variants in an average-risk cohort.
Rego S; Dagan-Rosenfeld O; Zhou W; Sailani MR; Limcaoco P; Colbert E; Avina M; Wheeler J; Craig C; Salins D; Röst HL; Dunn J; McLaughlin T; Steinmetz LM; Bernstein JA; Snyder MP
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30487145
[TBL] [Abstract][Full Text] [Related]
5. The burden of pathogenic variants in clinically actionable genes in a founder population.
Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
[TBL] [Abstract][Full Text] [Related]
6. Clinical exome-based panel testing for medically actionable secondary findings in a cohort of 383 Italian participants.
Martone S; Buonagura AT; Marra R; Rosato BE; Del Giudice F; Bonfiglio F; Capasso M; Iolascon A; Andolfo I; Russo R
Front Genet; 2022; 13():956723. PubMed ID: 36437915
[No Abstract] [Full Text] [Related]
7. Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
Chetruengchai W; Shotelersuk V
J Hum Genet; 2022 Mar; 67(3):137-142. PubMed ID: 34621001
[TBL] [Abstract][Full Text] [Related]
8. Copy number alterations involving 59 ACMG-recommended secondary findings genes.
Yatsenko SA; Aarabi M; Hu J; Surti U; Ortiz D; Madan-Khetarpal S; Saller DN; Bellissimo D; Rajkovic A
Clin Genet; 2020 Dec; 98(6):577-588. PubMed ID: 33009833
[TBL] [Abstract][Full Text] [Related]
9. Identification of Medically Actionable Secondary Findings in the 1000 Genomes.
Olfson E; Cottrell CE; Davidson NO; Gurnett CA; Heusel JW; Stitziel NO; Chen LS; Hartz S; Nagarajan R; Saccone NL; Bierut LJ
PLoS One; 2015; 10(9):e0135193. PubMed ID: 26332594
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
[TBL] [Abstract][Full Text] [Related]
12. Pilot Study of Return of Genetic Results to Patients in Adult Nephrology.
Nestor JG; Marasa M; Milo-Rasouly H; Groopman EE; Husain SA; Mohan S; Fernandez H; Aggarwal VS; Ahram DF; Vena N; Bogyo K; Bomback AS; Radhakrishnan J; Appel GB; Ahn W; Cohen DJ; Canetta PA; Dube GK; Rao MK; Morris HK; Crew RJ; Sanna-Cherchi S; Kiryluk K; Gharavi AG
Clin J Am Soc Nephrol; 2020 May; 15(5):651-664. PubMed ID: 32299846
[TBL] [Abstract][Full Text] [Related]
13. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes.
Jang MA; Lee SH; Kim N; Ki CS
Genet Med; 2015 Dec; 17(12):1007-11. PubMed ID: 25856671
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of the validated monogenic causes of human male infertility: 2020 update and a discussion of emerging gene-disease relationships.
Houston BJ; Riera-Escamilla A; Wyrwoll MJ; Salas-Huetos A; Xavier MJ; Nagirnaja L; Friedrich C; Conrad DF; Aston KI; Krausz C; Tüttelmann F; O'Bryan MK; Veltman JA; Oud MS
Hum Reprod Update; 2021 Dec; 28(1):15-29. PubMed ID: 34498060
[TBL] [Abstract][Full Text] [Related]
15. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory.
Punj S; Akkari Y; Huang J; Yang F; Creason A; Pak C; Potter A; Dorschner MO; Nickerson DA; Robertson PD; Jarvik GP; Amendola LM; Schleit J; Simpson DK; Rope AF; Reiss J; Kauffman T; Gilmore MJ; Himes P; Wilfond B; Goddard KAB; Richards CS
Am J Hum Genet; 2018 Jun; 102(6):1078-1089. PubMed ID: 29754767
[TBL] [Abstract][Full Text] [Related]
16. Actionable Exomic Secondary Findings in 280 Lebanese Participants.
Jalkh N; Mehawej C; Chouery E
Front Genet; 2020; 11():208. PubMed ID: 32231684
[TBL] [Abstract][Full Text] [Related]
17. Optimizing clinical exome design and parallel gene-testing for recessive genetic conditions in preconception carrier screening: Translational research genomic data from 14,125 exomes.
Capalbo A; Valero RA; Jimenez-Almazan J; Pardo PM; Fabiani M; Jiménez D; Simon C; Rodriguez JM
PLoS Genet; 2019 Oct; 15(10):e1008409. PubMed ID: 31589614
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for returning genomic incidental findings? We need to talk!
Burke W; Antommaria AH; Bennett R; Botkin J; Clayton EW; Henderson GE; Holm IA; Jarvik GP; Khoury MJ; Knoppers BM; Press NA; Ross LF; Rothstein MA; Saal H; Uhlmann WR; Wilfond B; Wolf SM; Zimmern R
Genet Med; 2013 Nov; 15(11):854-9. PubMed ID: 23907645
[TBL] [Abstract][Full Text] [Related]
19. 1 in 38 individuals at risk of a dominant medically actionable disease.
Haer-Wigman L; van der Schoot V; Feenstra I; Vulto-van Silfhout AT; Gilissen C; Brunner HG; Vissers LELM; Yntema HG
Eur J Hum Genet; 2019 Feb; 27(2):325-330. PubMed ID: 30291343
[TBL] [Abstract][Full Text] [Related]
20. Frequency and management of medically actionable incidental findings from genome and exome sequencing data: a systematic review.
Elfatih A; Mohammed I; Abdelrahman D; Mifsud B
Physiol Genomics; 2021 Sep; 53(9):373-384. PubMed ID: 34250816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
